Ola Wallengren1, Britt-Marie Iresjö, Kent Lundholm, Ingvar Bosaeus. 1. Department of Endocrinology, Diabetology and Metabolism, Sahlgrenska University Hospital, Dietistmotagningen, Per Dubbsgatan 14, 413 45, Gothenburg, Sweden, ola.wallengren@vgregion.se.
Abstract
PURPOSE: Muscle mass depletion is associated with adverse outcomes in cancer patients. There is limited information on the impact of age, sex, tumor type, and inflammation on muscle loss in the end of life of cancer patients. METHODS: Muscle depletion and loss of muscle in the last 2 years of life was estimated in 471 cancer patients from 779 dual-energy X-ray absorptiometry scans. A linear mixed model was used to estimate the impact of age, sex, tumor type, and inflammation. RESULTS: Patients above median age (>71 years) had less muscle mass (-1.1 ± 0.3 kg, P < 0.001). Prevalence of muscle depletion was higher in men than women (59 vs. 28%, P < 0.001). Men lost muscle mass over time (mean, 1.4 ± 0.3 kg/year, P < 0.001) contrary to women (0.3 ± 0.4 kg/year, P = 0.5). Patients with pancreatic cancer had less muscle mass than patients with biliary tract and colorectal cancers (P < 0.02). There were no differences in muscle loss over time in patients grouped by median age or tumor type. The prevalence of elevated C-reactive protein was 61 to 70% during the study. Patients with C-reactive protein >10 mg/L had less muscle mass (0.6 ± 0.2 kg, P < 0.001) and lost muscle mass at an accelerated pace during the disease trajectory (0.7 ± 0.3 kg/year, P = 0.03). CONCLUSIONS: Muscle loss in advanced cancer is related to age, sex, tumor type, and inflammation. The mechanism(s) behind the apparent sexual dimorphism warrants further study.
PURPOSE: Muscle mass depletion is associated with adverse outcomes in cancerpatients. There is limited information on the impact of age, sex, tumor type, and inflammation on muscle loss in the end of life of cancerpatients. METHODS: Muscle depletion and loss of muscle in the last 2 years of life was estimated in 471 cancerpatients from 779 dual-energy X-ray absorptiometry scans. A linear mixed model was used to estimate the impact of age, sex, tumor type, and inflammation. RESULTS:Patients above median age (>71 years) had less muscle mass (-1.1 ± 0.3 kg, P < 0.001). Prevalence of muscle depletion was higher in men than women (59 vs. 28%, P < 0.001). Men lost muscle mass over time (mean, 1.4 ± 0.3 kg/year, P < 0.001) contrary to women (0.3 ± 0.4 kg/year, P = 0.5). Patients with pancreatic cancer had less muscle mass than patients with biliary tract and colorectal cancers (P < 0.02). There were no differences in muscle loss over time in patients grouped by median age or tumor type. The prevalence of elevated C-reactive protein was 61 to 70% during the study. Patients with C-reactive protein >10 mg/L had less muscle mass (0.6 ± 0.2 kg, P < 0.001) and lost muscle mass at an accelerated pace during the disease trajectory (0.7 ± 0.3 kg/year, P = 0.03). CONCLUSIONS:Muscle loss in advanced cancer is related to age, sex, tumor type, and inflammation. The mechanism(s) behind the apparent sexual dimorphism warrants further study.
Authors: Katie M Di Sebastiano; Lin Yang; Kevin Zbuk; Raimond K Wong; Tom Chow; David Koff; Gerald R Moran; Marina Mourtzakis Journal: Br J Nutr Date: 2012-07-04 Impact factor: 3.718
Authors: Kent Lundholm; Ulla Körner; Lena Gunnebo; Petra Sixt-Ammilon; Marita Fouladiun; Peter Daneryd; Ingvar Bosaeus Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531
Authors: Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544
Authors: Carla M Prado; Michael B Sawyer; Sunita Ghosh; Jessica R Lieffers; Nina Esfandiari; Sami Antoun; Vickie E Baracos Journal: Am J Clin Nutr Date: 2013-08-21 Impact factor: 7.045
Authors: Judith Meza-Junco; Aldo J Montano-Loza; Vickie E Baracos; Carla M M Prado; Vincent G Bain; Crystal Beaumont; Nina Esfandiari; Jessica R Lieffers; Michael B Sawyer Journal: J Clin Gastroenterol Date: 2013 Nov-Dec Impact factor: 3.062
Authors: Jessica R Lieffers; Marina Mourtzakis; Kevin D Hall; Linda J McCargar; Carla M M Prado; Vickie E Baracos Journal: Am J Clin Nutr Date: 2009-02-25 Impact factor: 7.045
Authors: Robert D Kilgour; Antonio Vigano; Barbara Trutschnigg; Laura Hornby; Enriqueta Lucar; Simon L Bacon; José A Morais Journal: J Cachexia Sarcopenia Muscle Date: 2010-12-17 Impact factor: 12.910
Authors: Hannah E Wilson; Kacey K Rhodes; Daniel Rodriguez; Ikttesh Chahal; David A Stanton; Joseph Bohlen; Mary Davis; Aniello M Infante; Hannah Hazard-Jenkins; David J Klinke; Elena N Pugacheva; Emidio E Pistilli Journal: Clin Cancer Res Date: 2018-12-17 Impact factor: 12.531
Authors: Philippe Atlan; Mohamed Amine Bayar; Emilie Lanoy; Benjamin Besse; David Planchard; Jordy Ramon; Bruno Raynard; Sami Antoun Journal: Support Care Cancer Date: 2017-06-08 Impact factor: 3.603
Authors: Zackery S Fullerton; Benjamin D McNair; Nicholas A Marcello; Emily E Schmitt; Danielle R Bruns Journal: High Alt Med Biol Date: 2022-06-02 Impact factor: 2.183
Authors: Janine Krüger; Peter J Meffert; Lena J Vogt; Simone Gärtner; Antje Steveling; Matthias Kraft; Julia Mayerle; Markus M Lerch; Ali A Aghdassi Journal: PLoS One Date: 2016-11-18 Impact factor: 3.240
Authors: Susanne Blauwhoff-Buskermolen; Jacqueline A E Langius; Annemarie Becker; Henk M W Verheul; Marian A E de van der Schueren Journal: J Cachexia Sarcopenia Muscle Date: 2017-04-26 Impact factor: 12.910
Authors: Nichola Gale; David Wasley; Sioned Roberts; Karianne Backx; Annemarie Nelson; Robert van Deursen; Anthony Byrne Journal: Support Care Cancer Date: 2018-06-02 Impact factor: 3.603